Pharma Programmatic Strategy: An Investment Decision Guide

This guide is the entry point for the strategy and investment series. It does not reteach how auctions work. The pharma programmatic advertising guide covers the mechanics. This page is about how to make the investment calls.

Start with the commercial problem, not the channel

Most weak plans start with inventory: "we need CTV this year" or "we should test a new HCP partner." A stronger plan starts with a sentence the brand team and finance would both sign:

We believe [audience] is not [behavior] because [barrier], and media can reduce that barrier by [mechanism], which we will know by [evidence].

For example: prescribers in a specialty are aware of a newer therapy but are not initiating it with appropriate patients because they are unsure about patient selection, and media can reduce that uncertainty by repeating a clear, approved patient-identification message. That sentence already tells you the audience grain, the message job, the frequency logic, and the outcome you will look for.

The six decisions in order

Each decision constrains the next. If the objective is new patient starts in a narrow specialty, the audience is a validated prescriber list, the channel roles lean toward endemic and professional environments with video used for reach extension, and the measurement plan needs an Rx outcome study with a comparison group.

Separate commitments from options

Programmatic budgets are unusually reversible. Deals can be paused, bids changed, and partners swapped mid-flight. A good strategy uses that. Divide the plan into three parts:

• Committed base. Spend supported by prior evidence and needed to maintain presence. It should still carry a review date.
• Conditional scale. Spend that is released only if an observable trigger is met, such as a partner clearing a quality threshold in the first month.
• Learning reserve. Money explicitly set aside to answer a question the brand needs answered. See how much to reserve for learning.

This structure makes the plan easier to defend. When finance asks for a cut, you can show which dollars are protecting known value and which are optional bets.

Constraints that shape pharma plans

Pharma plans work inside constraints that generic programmatic advice ignores. Promotional content goes through medical, legal, and regulatory review, which limits how fast creative can change. Risk information requirements affect format choices, especially in short video and small display units. Health data carries privacy obligations that restrict which audiences can be built and how outcomes can be matched. The FDA's Office of Prescription Drug Promotion and HHS guidance on online tracking technologies are two starting points, not a substitute for your own review team.

Write the constraints into the plan as inputs. "Creative can refresh no more than once per quarter" changes your frequency strategy. "No condition-based audience segments for this indication" changes your targeting approach.

Measurement belongs in the plan, not the wrap report

Decide before launch which decisions the measurement must support. If the question is "should we keep this partner," you need partner-level results with enough volume to separate signal from noise. If the question is "does media create new prescriptions at all," you need a counterfactual design. The measurement design guide maps each decision to the minimum study that can support it.

The Media Rating Council's standards are useful for defining delivery metrics consistently. They do not tell you whether media changed prescribing. That requires a separate design.

Hypothetical example

A brand has $4 million for HCP programmatic. Last year it split spend evenly across four partners. A decision-based plan might look like this: $2.4 million committed to the two partners with the strongest prior outcome evidence, $0.8 million conditional on a new video partner meeting a target-list reach and quality threshold by week six, and $0.8 million held for a holdout test on the largest partner to estimate incremental prescriptions. These numbers are illustrative, not a recommended split.

Practical takeaway

Before approving any pharma programmatic plan, check that you can answer six questions in writing: the behavior change, the audience definition, each channel's job, the reason for each allocation, the decision each measurement supports, and the one question the learning budget will answer. If an answer is missing, fix the plan before buying media.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.